Targeting the hsa_circ_0000253/miR‐7/COL5A2 Axis: Unveiling CCT‐018159's Role in Halting Osteosarcoma Progression
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Xu Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering, Ocean Technology and Life Science, Dalian University of Technology, Panjin, China. Hauptthemen laut MEDLINE: MicroRNAs, Osteosarcoma, RNA, Circular, Collagen Type V. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: This study was supported by the Fundamental Research Funds for the Central Universities (grant number: DUT22YG107), the National Natural Science Foundation of….
Abstract (Originalsprache)
Osteosarcoma (OS) is the most common malignant bone tumor in children and adolescents, marked by aggressive local invasion and early metastasis. This study investigated the regulatory role of the hsa_circ_0000253/miR‐7/COL5A2 axis and the therapeutic potential of CCT‐018159 in OS progression. Differential expression and ceRNA network analyses identified hsa_circ_0000253 as a key regulator. Functional experiments demonstrated that silencing hsa_circ_0000253 or COL5A2 suppressed OS cell proliferation and migration, whereas inhibition of miR‐7 enhanced these processes. Single‐cell transcriptomics revealed distinct OS cell subclusters, with high‐risk cells characterized by elevated expression of COL5A2, IGF1R, COL1A1, and COL1A2, indicating progression toward aggressive phenotypes. Molecular docking further identified CCT‐018159 as a candidate drug capable of markedly reducing OS cell proliferation and migration. These findings highlight the hsa_circ_0000253/miR‐7/COL5A2 axis as a critical driver of OS malignancy and suggest CCT‐018159 as a promising therapeutic agent, warranting further in vivo validation and clinical exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical Engineering, Ocean Technology and Life Science, Dalian University of Technology, Panjin, China.
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China.
- Department of Pathology, Yingkou Fangda Hospital, Yingkou, China.
- Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
- Department of Training, Research, and Foreign Affairs, National Center for Pathology, Ulaanbaatar, Mongolia.
- Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, Egypt.
ORCID-Profile: Xu Guo, Mahmoud A A Ibrahim, Yanshuo Han, Jinzhu Liu
Förderung
- This study was supported by the Fundamental Research Funds for the Central Universities (grant number: DUT22YG107), the National Natural Science Foundation of…
Zitieren
APA
Guo, X., Zhu, X., Tian, X., Dai, Y., Tsedenbal, B., Ibrahim, M. A. A., Han, Y., & Liu, J. (2025). Targeting the hsa_circ_0000253/miR‐7/COL5A2 Axis: Unveiling CCT‐018159's Role in Halting Osteosarcoma Progression. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70464
Vancouver
Guo X, Zhu X, Tian X, Dai Y, Tsedenbal B, Ibrahim MAA, et al. Targeting the hsa_circ_0000253/miR‐7/COL5A2 Axis: Unveiling CCT‐018159's Role in Halting Osteosarcoma Progression. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70464
BibTeX
@article{Guo2025,
author = {Guo, Xu and Zhu, Xiangrui and Tian, Xin and Dai, Yunfeng and Tsedenbal, Batchimeg and Ibrahim, Mahmoud A A and Han, Yanshuo and Liu, Jinzhu},
title = {Targeting the hsa_circ_0000253/miR‐7/COL5A2 Axis: Unveiling CCT‐018159's Role in Halting Osteosarcoma Progression},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70464}
}
EUVIMED